Skip to content

Study · Observational study · 2023

3 results

Interview-Based Patient- and Caregiver-Reported Experiences of Hunger and Improved Quality of Life with Setmelanotide Treatment in Bardet-Biedl Syndrome.

Ervin C, Norcross L, Mallya UG, Fehnel S, Mittleman RS, Webster M, Haqq AM, Haws RM

Advances in therapy24 Mar 2023Cited by 19 (Europe PMC)

PMID36961653 (opens in a new tab)PMCIDPMC10036981 (opens in a new tab)DOI10.1007/s12325-023-02443-y (opens in a new tab)PepBankPUB-36961653
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    All interviewed patients with Bardet-Biedl syndrome and caregivers reported improved hunger and health during setmelanotide, including weight loss and less food preoccupation.

    In plain wordsPatients with Bardet-Biedl syndrome and caregivers reported better hunger and health during setmelanotide than before treatment.

    Peptide
    Setmelanotide
    Outcome
    Direction not reportedReported hunger and health outcomes
    Study

    n: not reported in source

    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    All participants experienced or observed improvements in hunger and health outcomes during treatment, the most meaningful of which included weight loss and decrease in obsessive focus on food and food-seeking behaviors.
    2 context sentences
    Summary · context
    Patients with BBS or their caregivers who participated in clinical trials of the MC4R agonist setmelanotide (NCT03013543 and NCT03746522) were included in this qualitative study.
    Summary · context
    Telephone interviews were conducted using a semistructured interview guide to explore patient experience and caregiver observations of hyperphagia before and during setmelanotide treatment.
  2. 02HumanObservational studyEfficacy outcome

    All interviewed patients with Bardet-Biedl syndrome and caregivers reported improved physical or emotional well-being during setmelanotide.

    In plain wordsAll interviewed patients and caregivers reported better physical or emotional well-being during setmelanotide than before treatment.

    Peptide
    Setmelanotide
    Outcome
    IncreasePhysical or emotional well-being
    Study

    n: not reported in source

    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    All participants reported improvements in either physical and/or emotional well-being and being satisfied with setmelanotide.
    2 context sentences
    Summary · context
    Patients with BBS or their caregivers who participated in clinical trials of the MC4R agonist setmelanotide (NCT03013543 and NCT03746522) were included in this qualitative study.
    Summary · context
    Telephone interviews were conducted using a semistructured interview guide to explore patient experience and caregiver observations of hyperphagia before and during setmelanotide treatment.
  3. 03HumanObservational studyEfficacy outcome

    All interviewed patients with Bardet-Biedl syndrome and caregivers reported satisfaction with setmelanotide.

    In plain wordsAll interviewed patients with Bardet-Biedl syndrome and caregivers were satisfied with setmelanotide.

    Peptide
    Setmelanotide
    Outcome
    Not applicableTreatment satisfaction
    Study

    n: not reported in source

    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    All participants reported improvements in either physical and/or emotional well-being and being satisfied with setmelanotide.
    2 context sentences
    Summary · context
    Patients with BBS or their caregivers who participated in clinical trials of the MC4R agonist setmelanotide (NCT03013543 and NCT03746522) were included in this qualitative study.
    Summary · context
    Telephone interviews were conducted using a semistructured interview guide to explore patient experience and caregiver observations of hyperphagia before and during setmelanotide treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03746522

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

Rhythm Pharmaceuticals, Inc.n = 5223 Nov 2018 to 8 Mar 2021

Bardet Biedl Syndrome (BBS) · Alström Syndrome (AS)

Trial pageClinicalTrials.govUpdated 1 Dec 2023
CompletedPhase 2Results postedNCT03013543

Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity

Rhythm Pharmaceuticals, Inc.n = 21310 Feb 2017 to 1 Mar 2022

Genetic Obesity · Obesity · Obesity Due to Melanocortin 4 Receptor Deficiency

Trial pageClinicalTrials.govUpdated 18 Aug 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.